These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 21443263)

  • 1. Development of a cell-selective and intrinsically active multikinase inhibitor bioconjugate.
    Harmsen S; Dolman ME; Nemes Z; Lacombe M; Szokol B; Pató J; Kéri G; Orfi L; Storm G; Hennink WE; Kok RJ
    Bioconjug Chem; 2011 Apr; 22(4):540-5. PubMed ID: 21443263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinum complex as a nanomolar protein kinase inhibitor.
    Williams DS; Carroll PJ; Meggers E
    Inorg Chem; 2007 Apr; 46(8):2944-6. PubMed ID: 17375909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and cytotoxic activity of benzopyran-based platinum(II) complexes.
    Gupta A; Mandal SK; Leblanc V; Descôteaux C; Asselin E; Bérubé G
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3982-7. PubMed ID: 18571403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and characterization of platinum(II) oxadiazoline complexes and their in vitro antitumor activity in platinum-sensitive and -resistant cancer cell lines.
    Coley HM; Sarju J; Wagner G
    J Med Chem; 2008 Jan; 51(1):135-41. PubMed ID: 18072719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative self-sorting synthesis of a Fe8Pt6L24 cubic cage.
    Smulders MM; Jiménez A; Nitschke JR
    Angew Chem Int Ed Engl; 2012 Jul; 51(27):6681-5. PubMed ID: 22674771
    [No Abstract]   [Full Text] [Related]  

  • 8. Synthesis and in vitro cytotoxicity of novel hydrophilic chiral 2-alkoxy-1,4-butanediamine platinum (II) complexes.
    Zhu H; Cui K; Wang L; Gou S
    Bioorg Med Chem Lett; 2005 Nov; 15(22):4936-43. PubMed ID: 16169720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards the rational design of platinum(II) and gold(III) complexes as antitumour agents.
    Wang X; Guo Z
    Dalton Trans; 2008 Mar; (12):1521-32. PubMed ID: 18335133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal targeting of kinase inhibitors.
    Dolman ME; Fretz MM; Segers GJ; Lacombe M; Prakash J; Storm G; Hennink WE; Kok RJ
    Int J Pharm; 2008 Dec; 364(2):249-57. PubMed ID: 18550305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The preparation and characterization of trans-platinum(IV) complexes with unusually high cytotoxicity.
    Cubo L; Hambley TW; Sanz Miguel PJ; Carnero A; Navarro-Ranninger C; Quiroga AG
    Dalton Trans; 2011 Jan; 40(2):344-7. PubMed ID: 20936210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic activities, cellular uptake, gene regulation, and optical imaging of novel platinum(II) complexes.
    Gao J; Liu YG; Zingaro RA
    Chem Res Toxicol; 2009 Oct; 22(10):1705-12. PubMed ID: 19694485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro evaluation of dichloro-bis(pyrazole)palladium(II) and dichloro-bis(pyrazole)platinum(II) complexes as anticancer agents.
    Keter FK; Kanyanda S; Lyantagaye SS; Darkwa J; Rees DJ; Meyer M
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):127-38. PubMed ID: 18350297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells.
    Gonzalo T; Beljaars L; van de Bovenkamp M; Temming K; van Loenen AM; Reker-Smit C; Meijer DK; Lacombe M; Opdam F; Kéri G; Orfi L; Poelstra K; Kok RJ
    J Pharmacol Exp Ther; 2007 Jun; 321(3):856-65. PubMed ID: 17369283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Organoplatinum(II) complexes with nucleobase motifs as inhibitors of human topoisomerase II catalytic activity.
    Wang P; Leung CH; Ma DL; Lu W; Che CM
    Chem Asian J; 2010 Oct; 5(10):2271-80. PubMed ID: 20730852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, characterization, and cytotoxic activity of novel platinum (II) complexes derived from n-benzyl-ethylenediamine and oxalate.
    Silva H; Barra CV; Rocha FV; de Almeida MV; Cesar ET; da Silva Siqueira LM; Lopes MT; Fontes AP
    Chem Biol Drug Des; 2010 Apr; 75(4):407-11. PubMed ID: 20102368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of Rho kinase inhibitors (II).
    Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Ohashi H; Sato M; Sugiyama T; Fukushima K; Iijima H
    Bioorg Med Chem; 2007 Jan; 15(1):350-64. PubMed ID: 17046269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A; Scholar EM
    J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxicity of cis-platinum(II) conjugate models. The effect of chelating arms and leaving groups on cytotoxicity: a quantitative structure-activity relationship approach.
    Monti E; Gariboldi M; Maiocchi A; Marengo E; Cassino C; Gabano E; Osella D
    J Med Chem; 2005 Feb; 48(3):857-66. PubMed ID: 15689170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.